CFDE Data Portal | Search RPL7P19

	Label	Description
	RPL7P19 Gene (Entity type)	ENSG00000241458 - ribosomal protein L7 pseudogene 19
	GSE195663 cisplatin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 7 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE165960 MEK inhibition 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE80098 GSE80366 progesterone 0 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE192750 adipose overexpression Grunt Fin PNMR OE 5 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE138863 disulfiram 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE176008 pyridoxine 7 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE171988 MBNL knockout Schneider 1 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE209533 disulfiram 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS

RPL7P19

ENSG00000241458 - ribosomal protein L7 pseudogene 19

GSE195663 cisplatin 0 v 1 human up

A Gene Set from LINCS

GSE195663 cisplatin 7 v 1 human up

A Gene Set from LINCS

GSE165960 MEK inhibition 0 v 1 human dn

A Gene Set from LINCS

GSE80098 GSE80366 progesterone 0 v 8 human up

A Gene Set from LINCS

GSE192750 adipose overexpression Grunt Fin PNMR OE 5 v 4 human dn

A Gene Set from LINCS

GSE138863 disulfiram 2 v 0 human up

A Gene Set from LINCS

GSE176008 pyridoxine 7 v 3 human up

A Gene Set from LINCS

GSE171988 MBNL knockout Schneider 1 1 v 0 human dn

A Gene Set from LINCS

GSE209533 disulfiram 0 v 1 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.